Vor Biopharma Inc.

VOR

$20.59

+$2.20 (11.96%)

Closed

FTSE Russell index inclusions spark continued 15% surge in Vor Biopharma shares

Loading chart...

IndexN/A

Market Cap0.14B

Enterprise Value-0.26B

Income$-0.03B

Sales$0.00B

EmployeesN/A

P/E-6.52

P/SN/A

P/B-0.79

P/C-0.90

EV/EBITDA0.38

EV/SalesN/A

EPS (ttm)-3.16

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume3.91M

Shs Outstand0.01B

Change11.96%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jul 205:30PMVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(globenewswire.com)05:30PMVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(globenewswire.com)

Jun 808:31AMTelitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China(globenewswire.com)08:30AMTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China(globenewswire.com)

Insider Trading

View All

Insider

Type

Price

Value

Date

Levin Andrew David

Award

57.2K

$14.09

$805K

Jun 11, 26

Beckman Daniella

Award

53.3K

$14.09

$751K

Jun 11, 26

Cumbo Alexander

Award

56.3K

$14.09

$794K

Jun 11, 26

Kalir Erez

Award

57.2K

$14.09

$805K

Jun 11, 26

Joustra Wouter

Award

57.2K

$14.09

$805K

Jun 11, 26

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

CEO: Jean-Paul KressEmployees: 159www.vorbio.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	$3.49M	$8.96M	N/A	N/A	$91.00K	$20.00K
Gross Profit	N/A	$-3.49M	$-8.96M	N/A	N/A	$-91.00K	$-20.00K
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$121.19M	$122.54M	$84.46M	$69.02M	$43.37M	$10.33M	$2.84M
Operating Income	$-121.19M	$-126.04M	$-93.42M	$-69.02M	$-43.37M	$-10.42M	$-2.86M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-116.91M	$-117.86M	$-92.09M	$-68.90M	$-43.34M	$-10.84M	$-4.15M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-34.00	$-35.00	$-46.60	$-37.80	$-26.60	$-6.20	$-14.60
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Vor Biopharma Inc.

Insider Trading

Discover more